<?xml version="1.0" encoding="UTF-8"?>
<p>Yurttas et al. obtained 2–(4-aminophenyl)BTA derivatives substituted with different heterocyclic rings and tested their antitumor potential against 60 human tumour cell lines. The BTA derivatives 
 <bold>13</bold> (2–(1
 <italic>H</italic>-benzo[d]imidazol-2-ylthio)-
 <italic>N</italic>-(4-(benzo[d]thiazol-2-yl)-3-chlorophenyl) acetamide) (
 <xref ref-type="fig" rid="F0008">Figure 8</xref>) and 
 <bold>14</bold> (
 <italic>N</italic>-(4-(benzo[d]thiazol-2-yl)phenyl)-2-(1-phenyl-1
 <italic>H</italic>-benzo[
 <italic>d]</italic>imidazol-2-yl-thio)-acetamide) (
 <xref ref-type="fig" rid="F0008">Figure 8</xref>) showed remarkable antitumor potential against different cancer cell lines. The heterocylic substitutions affect the activity and antitumor potential of these BTA derivatives, with derivative 
 <bold>14</bold> having comparable antitumor potential with the standard drugs whereas derivative 
 <bold>13</bold> being less active compared to 
 <bold>14</bold>. The order overall antitumor potential of 2–(4-aminophenyl) benzothiazole derivatives with reference to the heterocyclic substitution was benzimidazole 
 <inline-formula id="ilm0001">
  <alternatives>
   <inline-graphic xlink:href="IENZ_A_1698036_ILM0001.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
   <math id="d2e629">
    <mo>≥</mo>
   </math>
  </alternatives>
 </inline-formula> imidazole &gt; benzothiazole &gt; benzoxazole
 <xref rid="CIT0028" ref-type="bibr">
  <sup>28</sup>
 </xref>.
</p>
